Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
Acumen Pharmaceuticals’ investigational amyloid therapy failed to improve cognitive and function in Alzheimer’s disease during a mid-stage study, prompting the…
Acumen Pharmaceuticals’ investigational amyloid therapy failed to improve cognitive and function in Alzheimer’s disease during a mid-stage study, prompting the…